About Cidara Therapeutics (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-1.95752365434219
Forward P/E Ratio-2.02
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$5.29 per share
Price / Book1.27
Return on Equity-82.17%
Return on Assets-65.11%
Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions
What is Cidara Therapeutics' stock symbol?
Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."
How were Cidara Therapeutics' earnings last quarter?
Cidara Therapeutics Inc (NASDAQ:CDTX) announced its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.21. View Cidara Therapeutics' Earnings History.
Where is Cidara Therapeutics' stock going? Where will Cidara Therapeutics' stock price be in 2018?
9 equities research analysts have issued 1-year price targets for Cidara Therapeutics' stock. Their predictions range from $10.00 to $20.00. On average, they anticipate Cidara Therapeutics' stock price to reach $14.28 in the next twelve months. View Analyst Ratings for Cidara Therapeutics.
What are Wall Street analysts saying about Cidara Therapeutics stock?
Here are some recent quotes from research analysts about Cidara Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "We are positive on Cidara ahead of Phase 2 CD101 IV data (STRIVE study) for the treatment of systemic infections in early to mid-March. Our estimate on the timing of data release stems from the fact that the last patient, last visit (LPLV) was last week." (1/19/2018)
- 2. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (1/12/2018)
- 3. Needham & Company LLC analysts commented, "Cidara mgmt provided a corporate update at an Investor Day in NYC last week and we separately hosted a series of mtgs w/ investors. Mgmt reiterated guidance for top-line results from ongoing Phase 2 trial of CD101 in Invasive Candida infections in 4Q17. The trial is expected to serve as the first of two registration trials. Given discontinuation of CD101 Vulvovaginal Candidiasis program, mgmt introduced plans to instead accelerate development in antifungal prophylaxis. KOLs highlighted differentiation from other echinocandins, w/ emphasis on PK/PD profile and opportunity for better clinical outcomes. New details around Cloudbreak candidates were also announced, although clinical testing not expected until 2018. Stock is attractive ahead of Phase 2 CD101 results later this year (EV $15M)." (4/10/2017)
Who are some of Cidara Therapeutics' key competitors?
Some companies that are related to Cidara Therapeutics include Zymeworks (ZYME), Ardelyx (ARDX), MaxCyte (MXCT), Faron Pharmaceuticals Oy (FARN), Cellular Biomedicine Group (CBMG), Molecular Templates (MTEM), Kindred Biosciences (KIN), Chimerix (CMRX), Tocagen (TOCA), Foamix Pharmaceuticals (FOMX), Bellicum Pharmaceuticals (BLCM), vTv Therapeutics (VTVT), Zafgen (ZFGN), Minerva Neurosciences (NERV), Vital Therapies (VTL), Vascular Biogenics (VBLT), Selecta Biosciences (SELB) and ImmuPharma (IMM).
Who are Cidara Therapeutics' key executives?
Cidara Therapeutics' management team includes the folowing people:
- Scott M. Rocklage Ph.D., Chairman of the Board
- Jeffrey L. Stein Ph.D., President, Chief Executive Officer, Director (Age 62)
- Matthew W. Onaitis J.D., Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, General Counsel, Secretary (Age 45)
- Kenneth Bartizal Ph.D., Chief Development Officer (Age 63)
- Paul Daruwala, Chief Commercial Officer (Age 46)
- Kevin M. Forrest Ph.D., Chief Strategy Officer (Age 40)
- Taylor Sandison M.D., Chief Medical Officer
- Daniel D. Burgess, Director (Age 55)
- Timothy R. Franson M.D., Director (Age 65)
- Robert J. Perez, Director (Age 52)
When did Cidara Therapeutics IPO?
(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.
Who owns Cidara Therapeutics stock?
Cidara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Prosight Management LP (8.14%), Broadfin Capital LLC (4.24%), Millennium Management LLC (2.93%), Renaissance Technologies LLC (0.89%), Guggenheim Capital LLC (0.51%) and Deutsche Bank AG (0.40%). Company insiders that own Cidara Therapeutics stock include Jeffrey Stein, Kevin Forrest, Target N V Biotech and Taylor Sandison. View Institutional Ownership Trends for Cidara Therapeutics.
Who sold Cidara Therapeutics stock? Who is selling Cidara Therapeutics stock?
Who bought Cidara Therapeutics stock? Who is buying Cidara Therapeutics stock?
Cidara Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Prosight Management LP, Eversept Partners LLC, Renaissance Technologies LLC and Broadfin Capital LLC. Company insiders that have bought Cidara Therapeutics stock in the last two years include Jeffrey Stein, Kevin Forrest, Target N V Biotech and Taylor Sandison. View Insider Buying and Selling for Cidara Therapeutics.
How do I buy Cidara Therapeutics stock?
Shares of Cidara Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cidara Therapeutics' stock price today?
One share of Cidara Therapeutics stock can currently be purchased for approximately $6.70.
How big of a company is Cidara Therapeutics?
Cidara Therapeutics has a market capitalization of $137.62 million. The biotechnology company earns $-48,160,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Cidara Therapeutics employs 60 workers across the globe.
How can I contact Cidara Therapeutics?
Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]
MarketBeat Community Rating for Cidara Therapeutics (CDTX)MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cidara Therapeutics (NASDAQ:CDTX) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$14.28||$13.50||$13.85||$13.65|
|Price Target Upside: ||98.35% upside||87.50% upside||68.90% upside||121.95% upside|
Cidara Therapeutics (NASDAQ:CDTX) Consensus Price Target History
Cidara Therapeutics (NASDAQ:CDTX) Analyst Ratings History
(Data available from 2/23/2016 forward)
Cidara Therapeutics (NASDAQ:CDTX) Earnings History and Estimates Chart
Cidara Therapeutics (NASDAQ CDTX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017||Q3 2017||($0.94)||($0.73)||$0.18 million||View||N/A|
|8/9/2017||Q2 2017||($0.91)||($0.99)||$0.25 million||View||N/A|
Cidara Therapeutics (NASDAQ:CDTX) Earnings Estimates
2018 EPS Consensus Estimate: ($2.86)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Cidara Therapeutics (NASDAQ:CDTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Cidara Therapeutics (NASDAQ CDTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 18.90%
Institutional Ownership Percentage: 59.51%
Cidara Therapeutics (NASDAQ CDTX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/15/2017||Target N V Biotech||Major Shareholder||Buy||60,000||$7.57||$454,200.00||2,295,272|| |
|9/12/2017||Jeffrey Stein||CEO||Buy||7,350||$6.79||$49,906.50||51,851|| |
|6/7/2017||Taylor Sandison||Insider||Buy||20,000||$5.90||$118,000.00|| |
|6/5/2017||Jeffrey Stein||CEO||Buy||15,000||$5.95||$89,250.00|| |
|3/31/2017||Jeffrey Stein||CEO||Buy||12,900||$7.75||$99,975.00|| |
|3/31/2017||Kevin Forrest||Insider||Buy||12,500||$7.75||$96,875.00|| |
|5/20/2016||Jeffrey Stein||CEO||Buy||4,310||$11.51||$49,608.10||12,100|| |
|5/20/2016||Kevin Forrest||CFO||Buy||4,356||$11.53||$50,224.68||58,253|| |
|11/25/2015||Jeffrey Stein||CEO||Buy||6,700||$15.09||$101,103.00||6,700|| |
|11/23/2015||Kevin Forrest||CFO||Buy||7,087||$14.23||$100,848.01||51,719|| |
|4/20/2015||Timothy R Franson||Director||Buy||4,000||$16.00||$64,000.00|| |
Cidara Therapeutics (NASDAQ CDTX) News Headlines
|Reviewing Cidara Therapeutics (CDTX) & Paratek Pharmaceuticals (PRTK)|
www.americanbankingnews.com - February 19 at 3:20 PM
|Cidara Therapeutics Inc (CDTX) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - February 14 at 3:26 PM
|The Antimicrobials Working Group Announces the Appointment of Dr. Michael Dunne as Vice Chair|
finance.yahoo.com - January 30 at 3:19 PM
|Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting|
finance.yahoo.com - January 29 at 3:20 PM
|Cidara Therapeutics Inc (CDTX) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - January 20 at 5:38 PM
|Cidara Therapeutics (CDTX) Stock Rating Reaffirmed by Cantor Fitzgerald|
www.americanbankingnews.com - January 19 at 11:38 AM
|Cidara Therapeutics (CDTX) Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - January 12 at 7:26 PM
|Cidara Therapeutics (CDTX) Upgraded by Zacks Investment Research to "Buy"|
www.americanbankingnews.com - January 9 at 7:12 PM
|Head-To-Head Contrast: Cidara Therapeutics (CDTX) versus Its Competitors|
www.americanbankingnews.com - January 5 at 3:32 AM
|Expansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare Diseases|
www.businesswire.com - January 4 at 9:52 AM
|Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections|
finance.yahoo.com - January 4 at 9:52 AM
|Cidara Therapeutics Inc (CDTX) Given Consensus Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - December 26 at 4:39 PM
|Cidara Therapeutics (CDTX) Downgraded to Hold at Zacks Investment Research|
www.americanbankingnews.com - December 25 at 7:14 PM
|Analyzing Cidara Therapeutics (CDTX) and Its Peers|
www.americanbankingnews.com - December 17 at 1:28 AM
|Reviewing Cidara Therapeutics (CDTX) and Its Rivals|
www.americanbankingnews.com - December 12 at 8:48 AM
|Cidara Therapeutics, Inc. (CDTX) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - December 2 at 12:00 AM
|Cidara Therapeutics (CDTX) Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin in Invasive Fungal Infections|
www.streetinsider.com - November 30 at 4:56 PM
|Cidara Therapeutics Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin (CD101 IV) in Invasive Fungal Infections|
finance.yahoo.com - November 28 at 4:55 PM
|Cidara Therapeutics (CDTX) Given a $15.00 Price Target at Cantor Fitzgerald|
www.americanbankingnews.com - November 28 at 11:20 AM
|Cidara Therapeutics, Inc. (CDTX) Major Shareholder Target N. V. Biotech Buys 60,000 Shares|
www.americanbankingnews.com - November 16 at 4:24 PM
|Cidara Therapeutics Named a San Diego Metro Area 2017 Top Workplace|
finance.yahoo.com - November 13 at 11:11 PM
|Cidara Therapeutics, Inc. (CDTX) Expected to Earn FY2017 Earnings of ($3.14) Per Share|
www.americanbankingnews.com - November 13 at 3:58 AM
|Cidara Therapeutics, Inc. (CDTX) Forecasted to Earn Q3 2018 Earnings of ($0.72) Per Share|
www.americanbankingnews.com - November 10 at 4:20 PM
|Edited Transcript of CDTX earnings conference call or presentation 8-Nov-17 9:05pm GMT|
finance.yahoo.com - November 9 at 7:53 PM
|Cidara Therapeutics, Inc. (CDTX) Posts Earnings Results, Beats Expectations By $0.21 EPS|
www.americanbankingnews.com - November 9 at 12:44 AM
|5 Biotech Stocks Well Poised to Surpass Expectations in Q3|
finance.yahoo.com - November 7 at 8:00 PM
|Cidara Therapeutics, Inc. (CDTX) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - November 6 at 5:48 PM
|Cidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate Update|
finance.yahoo.com - November 1 at 5:51 PM
|Contrasting ADMA Biologics (ADMA) and Cidara Therapeutics (CDTX)|
www.americanbankingnews.com - October 26 at 11:36 AM
|Cidara Therapeutics, Inc. (CDTX) Raised to Buy at Zacks Investment Research|
www.americanbankingnews.com - October 25 at 5:26 PM
|QURE On Fast Track, Music To CNCE's Ears, CRBP Gets A Facelift, OBLN Deflated|
www.rttnews.com - October 19 at 10:36 PM
|Cidara Therapeutics (CDTX) Prices $20M Private Placement of Common Stock|
www.streetinsider.com - October 19 at 10:36 PM
|Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock|
finance.yahoo.com - October 19 at 5:34 PM
|Contrasting Spark Therapeutics (ONCE) & Cidara Therapeutics (CDTX)|
www.americanbankingnews.com - October 19 at 12:16 AM
|Cidara Therapeutics, Inc. (CDTX) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - October 12 at 6:56 PM
|Cidara Therapeutics (CDTX) & Aradigm Corporation (ARDM) Critical Analysis|
www.americanbankingnews.com - October 10 at 9:07 AM
|Cidara Therapeutics, Inc. (CDTX) Stock Rating Reaffirmed by Cantor Fitzgerald|
www.americanbankingnews.com - September 27 at 6:10 PM
|Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting|
finance.yahoo.com - September 25 at 7:44 PM
|Cidara Therapeutics to Present at Two Upcoming Conferences|
finance.yahoo.com - September 18 at 8:37 PM
|Cidara Therapeutics, Inc. (CDTX) CEO Acquires $49,906.50 in Stock|
www.americanbankingnews.com - September 12 at 8:24 PM
|Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress|
finance.yahoo.com - September 7 at 5:09 PM
|Antimicrobials Working Group Member Companies Announce Partnership and Exclusive Pricing Program|
www.prnewswire.com - September 6 at 10:05 PM
|Cidara Therapeutics, Inc. (CDTX) Short Interest Down 53.3% in August|
www.americanbankingnews.com - August 28 at 1:20 AM
|Brokers Issue Forecasts for Cidara Therapeutics, Inc.'s Q3 2017 Earnings (CDTX)|
www.americanbankingnews.com - August 16 at 7:22 AM
|Equities Analysts Offer Predictions for Cidara Therapeutics, Inc.'s FY2018 Earnings (CDTX)|
www.americanbankingnews.com - August 14 at 9:22 AM
|Leerink Swann Comments on Cidara Therapeutics, Inc.'s Q3 2017 Earnings (NASDAQ:CDTX)|
www.americanbankingnews.com - August 14 at 3:34 AM
|Cidara Therapeutics' (CDTX) Overweight Rating Reiterated at Cantor Fitzgerald|
www.americanbankingnews.com - August 12 at 6:34 AM
|Cidara Therapeutics, Inc. (CDTX) Upgraded to "Hold" at WBB Securities|
www.americanbankingnews.com - August 11 at 7:32 PM
|Cantor Fitzgerald Analysts Give Cidara Therapeutics, Inc. (CDTX) a $15.00 Price Target|
www.americanbankingnews.com - August 10 at 6:20 PM
|Cidara Therapeutics Inc (NASDAQ:CDTX) Announces Quarterly Earnings Results|
www.americanbankingnews.com - August 9 at 11:58 PM
Cidara Therapeutics (NASDAQ:CDTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cidara Therapeutics (NASDAQ:CDTX) Income Statement, Balance Sheet and Cash Flow Statement
Cidara Therapeutics (NASDAQ CDTX) Stock Chart for Friday, February, 23, 2018